First, he said obesity treatment should increasingly focus on improving overall healthnot just reducing weight alone
The PBMs denied the allegations and challenged the FTCs legal theory, arguing that the rebate system provides value to plan sponsors and that formulary decisions reflect competitive negotiations rather than anticompetitive coordination
Overall, 67% of the subjects treated with semaglutide achieved the ADA target HbA1c level of less than 7%, however, only 56% of the semaglutide-treated subjects achieved the target level without symptoms of hypoglycemia or weight gain
Cannot be spread across monthly payments through the Medicare Prescription Payment Plan
De Block C, Bailey C, Wysham C, Hemmingway A, Allen SE, Peleshok J
Epidemiology (Cambridge, Mass)